Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company headquartered in Foster City, California, with operations in more than 35 countries worldwide. The company's website is www.gilead.com. Gilead discovers, develops, and commercializes innovative medicines to prevent and treat life-threatening diseases, with a primary focus on virology, oncology, and inflammation.

The company's commercial portfolio includes more than 25 approved therapies addressing multiple therapeutic areas. In virology, Gilead markets HIV treatments including Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, and Yeztugo, along with hepatitis C and hepatitis B treatments such as Epclusa and Vemlidy. The company also offers Livdelzi for primary biliary cholangitis. In oncology, Gilead commercializes CAR T-cell therapies including Yescarta and Tecartus, as well as Trodelvy, a Trop-2 directed antibody-drug conjugate for breast cancer. Additional products include AmBisome for fungal infections and Veklury for COVID-19 treatment.

Gilead generates revenue through product sales, royalties from outbound intellectual property licenses, and payments from third-party collaborations. The company maintains U.S. and international commercial operations with marketing subsidiaries across more than 35 countries. In the United States, approximately 90 percent of gross product sales historically flow through three major wholesalers: Cardinal Health, Cencora, and McKesson Corporation, along with their specialty distributor affiliates.

The company operates multiple manufacturing facilities across the United States, Canada, Ireland, and the Netherlands, supporting both clinical development and commercial production. Gilead also relies on contract manufacturing organizations and contract testing laboratories to produce the majority of its active pharmaceutical ingredients and drug products. As of December 31, 2025, the company employed approximately 17,000 people.

Gilead maintains an extensive research and development pipeline with product candidates in Phase 3 clinical trials and pending regulatory review, particularly in HIV treatment, oncology, and viral hepatitis. The company pursues growth through strategic collaborations, in-licensing agreements, and acquisitions to enhance its commercial portfolio and advance transformational therapies addressing unmet medical needs.